Condition (MeSH)
Gliosarcoma
ClinicalTrials.gov lists 487 trials for Gliosarcoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 94.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
487 of the 487 trials are tagged with Gliosarcoma itself; the rest are tagged with a narrower condition beneath it.
When did Gliosarcoma trials start? (35)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 34
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 5 |
| 2022 | 4 |
| 2021 | 4 |
| 2020 | 7 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 9 |
Showing 10 of 35 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 393 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gliosarcoma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 175 |
| Phase 1/2 | 80 |
| Phase 2 | 178 |
| Phase 2/3 | 2 |
| Phase 3 | 19 |
| Not applicable | 18 |
| Observational | 15 |
How many Gliosarcoma trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 12 |
| Active, not recruiting | 20 |
| Completed | 340 |
| Suspended | 2 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gliosarcoma trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 94 |
| European Organisation for Research and Treatment of Cancer - EORTC | 13 |
| Radiation Therapy Oncology Group | 10 |
Which drugs are being tested for Gliosarcoma? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Irinotecan | 20 |
| O6-Benzylguanine | 12 |
| THALIDOMIDE | 8 |
| Temsirolimus | 8 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 119 |
| Radiation Therapy | 81 |
| Bevacizumab 1 | 35 |
| Carmustin | 24 |
| Adjuvant Therapy | 19 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Gliosarcoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Seizure | 393 | 73 |
| Platelet count decreased | 317 | 32 |
| Fatigue | 248 | 49 |
| Confusion | 155 | 46 |
| Lymphopenia | 153 | 12 |
Showing 5 of 10 adverse events.
Which publications cover Gliosarcoma? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 14 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Gliosarcoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Gliosarcoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Gliosarcoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Gliosarcoma | 251576 | Exact | Orphadata Science knowledge files, Product 1 |
| Gliosarcoma | 251576 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.